newsfilter
← Earnings
Earnings Releases·

MBX Biosciences — Third Quarter 2026 Earnings Summary

MBX Biosciences initiated its pivotal Phase 3 oPTimize trial for once-weekly canvuparatide in August 2026 to treat chronic hypoparathyroidism. The company remains on track to report unblinded 12-week multiple ascending dose data for its once-monthly obesity candidate MBX 4291 in the fourth quarter of 2026. Additionally, preclinical data for the triple agonist prodrug MBX 6180 has been accepted for presentation at ObesityWeek 2026. For the third quarter ended September 30, 2026, the company reported a net loss of $62.4 million and held $481.6 million in cash and investments, which is projected to fund operations into 2029.

Company
MBX BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology